Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.48 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514096 | 0.87 | PTGES (0.42) | PTGESACACBCXCR4FFAR1 | |
| SCHEMBL4514100 | 0.87 | PTGES (0.42) | PTGESACACBCXCR4FFAR1 | |
| SCHEMBL4516752 | 0.81 | PTGES (0.48) | PTGESACACBTBXAS1CXCR4FFAR1 | |
| SCHEMBL4516755 | 0.81 | PTGES (0.48) | PTGESACACBTBXAS1CXCR4FFAR1 | |
| SCHEMBL4523871 | 0.81 | FFAR1 (0.54) | PTGESACACBCXCR4FFAR1HDAC1 | |
| SCHEMBL4521338 | 0.79 | PTGES (0.45) | PTGESACACBTBXAS1 | |
| SCHEMBL4521332 | 0.79 | PTGES (0.45) | PTGESACACBTBXAS1 | |
| SCHEMBL4519671 | 0.76 | PTGES (0.45) | PTGESACACBCXCR4FFAR1HDAC1 | |
| SCHEMBL4503568 | 0.75 | PTGES (0.42) | PTGESACACBCXCR4FFAR1 | |
| SCHEMBL5706341 | 0.72 | PTGES (0.44) | PTGESACACBCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | PTGES 545/4885ACACB 410/4885TBXAS1 372/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | PTGES 626/4885ACACB 809/4885TBXAS1 1009/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | PTGES 545/4885ACACB 410/4885TBXAS1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.